Claritev Earnings Call Highlights Growth, AI and Deals

Claritev Corporation ((CTEV)) has held its Q1 earnings call. Read on for the main highlights of the call.

Claritev Corporation’s latest earnings call carried a clearly upbeat tone, as management highlighted revenue and EBITDA coming in ahead of expectations while reiterating confidence in full‑year profitability. Executives framed current spending as disciplined investment, pointing to surging ACV bookings, a rapidly expanding pipeline, and early AI-driven productivity gains as evidence that growth is strengthening beneath the surface.

Revenue Growth and Margin Resilience

Claritev reported Q1 revenue of $244.7 million, up 5.8% year over year, with adjusted EBITDA of $146.9 million, up 3.4% and translating to a robust 60% margin. Management nudged up the low end of its full‑year revenue outlook to a range of $985 million to $1.0 billion while keeping EBITDA guidance at $605 million to $615 million, signaling confidence in sustaining margins above 61%.

ACV Momentum and Larger Deal Wins

Annual contract value bookings reached $44.1 million in Q1, putting Claritev nearly halfway to its $80 million to $100 million full‑year target and implying 20% to 50% growth over last year. The company closed 19 deals above $100,000 ACV and nine above $1 million, a 350% jump in seven‑figure deals, as average deal size more than doubled and pipeline coverage improved to roughly 4.8 times quota.

Cash Flow Strengthening Despite Working Capital Drag

Unlevered free cash flow improved sharply to $36.8 million in Q1, an increase of 181% year over year and a gain of $23.7 million. Management reaffirmed expectations for positive free cash flow for the full year and kept capital spending plans in the $160 million to $170 million range, underscoring its ability to fund growth internally.

Core Products Drive Healthy Mix and Savings

The flagship claims intelligence product, Data iSight, remained a growth engine with its service line rising 8.4% in the quarter, while network and payment integrity offerings performed at or slightly above expectations. Even as PSAV volumes dipped modestly, Claritev offset the pressure through favorable rate and mix dynamics and higher‑acuity claims that boosted savings per claim.

Strategic Wins Broaden Market Reach

Claritev scored notable strategic wins, including a deal with GDIT to build a custom network for the World Trade Center Health Program, marking a significant step into the public sector. The company also secured a major contract with a top‑five health system operating more than 700 facilities, a win enabled by its Q4 acquisition of OPCG and the launch of new services.

AI Tools Lift Productivity and Cut Costs

Management highlighted that AI and code-assist tools have nearly doubled engineering coding capacity without increasing headcount, effectively expanding output at minimal incremental cost. The company also rolled out an AI‑powered provider contact agent and automated invoice processing, cutting process times by more than half, saving over 2,000 hours, and handling thousands of invoices daily with near‑perfect accuracy.

Improved Line of Sight to Future Revenue

Claritev emphasized growing confidence in future revenue as new bookings typically convert to revenue within six to twelve months and pipeline growth reached roughly 70% year over year. The company expects Q2 revenue to be roughly flat sequentially, followed by 3% to 5% growth in the second half as recent ACV wins begin to ramp into the top line, supporting its full‑year targets.

PSAV Volumes Under Modest Pressure

Not everything in Q1 was smooth, as PSAV claim volumes declined modestly, though management did not quantify the drop. Even so, the company maintained growth in that line by leaning on better pricing, a more favorable mix, and higher‑acuity claims that generated greater savings per claim, suggesting volume risk was manageable.

Cash Consumption Pattern and Interest Normalization

The quarter was a net cash consumption period, with free cash flow use reported at $92.5 million, driven by working capital build and fully annualized cash interest payments following last year’s refinancing. Management signaled that investors should expect Q1 and Q3 to be cash‑use quarters for now, framing this as a predictable pattern rather than a sign of underlying weakness.

Services Growth Weighs on Near-Term Margins

Claritev is leaning into services for providers and public sector clients, with services expected to account for about 20% of total ACV at the midpoint of guidance. However, these contracts carry margins roughly half those of the core business during the ramp phase, and the company plans an additional $20 million to $25 million of investment, meaning blended margins will face temporary dilution until scale and cross‑sell opportunities improve profitability.

One-Offs and Lagging EBITDA Growth

Comparisons are being muddied by prior-year one-time P&C and other revenues, roughly $5.4 million in each of last year’s Q2 through Q4 plus a referenced $18 million one‑time contribution, which will create headwinds in year-over-year metrics. At the same time, adjusted EBITDA growth of 3.4% lagged revenue growth of 5.8% in Q1, reflecting the impact of mix and investment, though management framed this as an acceptable trade-off for future expansion.

Regulatory and Market Unknowns Remain

Executives acknowledged that potential regulatory shifts, including possible changes around Medicare Advantage concurrent review, and broader market dynamics could influence volumes and demand over time. While they currently expect limited immediate impact from these factors, they remain watchful and presented them as key uncertainties on the horizon.

Guidance Reinforces Confidence in Second-Half Acceleration

Looking ahead, Claritev raised the bottom end of its revenue outlook to $985 million, kept the top end at $1.0 billion, and maintained adjusted EBITDA guidance at $605 million to $615 million, implying 61% to 62% margins and mid‑single digit EBITDA growth on a normalized basis. Backed by a 70% larger pipeline, nearly half of the annual ACV target already booked, ongoing AI efficiencies, and planned capital of $160 million to $170 million, management expects revenue growth to re‑accelerate to 3% to 5% in the second half and free cash flow conversion to normalize by year‑end.

Claritev’s earnings call painted a picture of a company balancing near-term investment with disciplined profitability, as strong bookings, expanding deal sizes, and AI-driven efficiencies underpin a largely positive outlook. While softer PSAV volumes, services-driven margin dilution, and regulatory uncertainties pose risks, management’s raised revenue floor and reaffirmed EBITDA guide suggest they see these as manageable bumps on an otherwise constructive growth path.